Sagimet Biosciences Inc (NASDAQ: SGMT) is a clinical-stage biopharmaceutical company developing small-molecule drug candidates targeting fatty acid synthesis pathways. The company generates no product revenue and funds operations entirely through existing cash, cash equivalents, and marketable securities while spending on clinical development and manufacturing. As of the 10-K filed March 11, 2026, Sagimet's primary asset is denifanstat, a fatty acid synthase (FASN) inhibitor in clinical development for metabolic dysfunction-associated steatohepatitis (MASH), with a Phase 3 trial underway and a Phase 1 pharmacokinetic trial evaluating the combination of denifanstat and resmetirom. A second candidate, TVB-3567, was also in clinical development as of the same filing. Net cash used in operating activities was $45.7 million for the year ended December 31, 2025, compared to $42.4 million for the year ended December 31, 2024, reflecting ongoing trial costs and public-company infrastructure spend.

Revenue model

Pre-revenue clinical-stage company. No product sales as of the 10-K filed March 11, 2026. Operations are funded by cash reserves and proceeds from marketable securities. Other income consists primarily of interest earned on cash, cash equivalents, and marketable securities.

Products and services

Denifanstat: a FASN inhibitor in Phase 3 development for MASH and in a Phase 1 pharmacokinetic trial in combination with resmetirom. TVB-3567: a second drug candidate in clinical development. Both are small-molecule compounds targeting fatty acid synthesis (per 10-K filed 2026-03-11).

Customers and end markets

No commercial customers as of the filing date. Target end market is patients with MASH (metabolic dysfunction-associated steatohepatitis). Future customers would include payors, hospitals, and specialty pharmacies upon any regulatory approval.

Value-chain role

Drug developer relying on third-party contract research organizations (CROs) and contract manufacturing organizations (CMOs) for clinical-trial execution and drug supply. Sagimet does not own manufacturing facilities.

Geographic exposure

Primarily U.S.-based operations. Regulatory filings reference FDA oversight as primary pathway. Filing also references EU, UK (MHRA), and other international regulatory regimes as potential future markets, though no commercial operations outside the U.S. are described (per 10-K filed 2026-03-11).

Source: SEC 10-K, filed 2026-03-11

Industry: Pharmaceutical Preparations Peers: Acrivon Therapeutics Inc Anika Therapeutics Inc Astria Therapeutics, Inc. Enanta Pharmaceuticals Inc Sutro Biopharma Inc Ovid Therapeutics Inc Onkure Therapeutics Inc Vanda Pharmaceuticals Inc